Angiotensin II type 1 receptor antagonist protects ventricular and coronary endothelial function after 24-hour heart preservation

Noriyoshi Kajihara, Takahiro Nishida, Noriko Boku, Hideki Tatewaki, Masataka Eto, Shigeki Morita

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Angiotensin II type 1 (AT1) receptor antagonists may enhance the cyclic guanosine monophosphate-nitric oxide system and thereby attenuate ventricular and coronary endothelial dysfunction after heart preservation. Methods: We used an isolated rabbit heart preparation perfused with blood from a support rabbit. The rabbit heart was excised, stored for 24 hours, and then perfused with blood from a support rabbit that was treated with an AT1 receptor antagonist (telmisartan; 5 mg/kg) or solvent. We evaluated the cardiac output with the working preparation, and coronary blood flow and coronary endothelial function with the Langendorff preparation. In addition, we measured the serum nitric oxide level in the coronary effluent. Results: The Telmisartan Group showed higher plasma angiotensin II levels (928.6 ± 136.2 vs 271.6 ± 81.6 pg/ml, p < 0.01), better cardiac output (116.2 ± 5.4 vs 88.8 ± 7.1 ml/min, p < 0.05), and higher coronary blood flow (25.0 ± 2.2 vs 14.9 ± 1.3 ml/min, p < 0.01). The coronary blood flow in response to acetylcholine was higher in the Telmisartan Group (47.8 ± 3.9 vs 28.0 ± 2.1 ml/min, p < 0.01), but there was no difference in response to sodium nitroprusside. The Telmisartan Group showed higher serum nitric oxide levels in the coronary effluent (33.9 ± 4.6 vs 20.6 ± 3.3 μmol/liter, p < 0.05). Conclusions: Treatment with the AT1 receptor antagonist improved ventricular and endothelial function after 24-hour heart preservation. These data imply that AT1 activation plays a critical role in reperfusion injury. AT1 receptor blockade may be a promising strategy for long-term heart preservation.

Original languageEnglish
Pages (from-to)2211-2217
Number of pages7
JournalJournal of Heart and Lung Transplantation
Volume24
Issue number12
DOIs
Publication statusPublished - Dec 1 2005

Fingerprint

Angiotensin II Type 1 Receptor Blockers
Rabbits
Nitric Oxide
Angiotensin II
Cardiac Output
Angiotensin Type 1 Receptor
Ventricular Function
Cyclic GMP
Nitroprusside
Reperfusion Injury
Serum
Acetylcholine
telmisartan

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Cite this

Angiotensin II type 1 receptor antagonist protects ventricular and coronary endothelial function after 24-hour heart preservation. / Kajihara, Noriyoshi; Nishida, Takahiro; Boku, Noriko; Tatewaki, Hideki; Eto, Masataka; Morita, Shigeki.

In: Journal of Heart and Lung Transplantation, Vol. 24, No. 12, 01.12.2005, p. 2211-2217.

Research output: Contribution to journalArticle

Kajihara, Noriyoshi ; Nishida, Takahiro ; Boku, Noriko ; Tatewaki, Hideki ; Eto, Masataka ; Morita, Shigeki. / Angiotensin II type 1 receptor antagonist protects ventricular and coronary endothelial function after 24-hour heart preservation. In: Journal of Heart and Lung Transplantation. 2005 ; Vol. 24, No. 12. pp. 2211-2217.
@article{aaabd8e3fea94b44be795c409260478c,
title = "Angiotensin II type 1 receptor antagonist protects ventricular and coronary endothelial function after 24-hour heart preservation",
abstract = "Background: Angiotensin II type 1 (AT1) receptor antagonists may enhance the cyclic guanosine monophosphate-nitric oxide system and thereby attenuate ventricular and coronary endothelial dysfunction after heart preservation. Methods: We used an isolated rabbit heart preparation perfused with blood from a support rabbit. The rabbit heart was excised, stored for 24 hours, and then perfused with blood from a support rabbit that was treated with an AT1 receptor antagonist (telmisartan; 5 mg/kg) or solvent. We evaluated the cardiac output with the working preparation, and coronary blood flow and coronary endothelial function with the Langendorff preparation. In addition, we measured the serum nitric oxide level in the coronary effluent. Results: The Telmisartan Group showed higher plasma angiotensin II levels (928.6 ± 136.2 vs 271.6 ± 81.6 pg/ml, p < 0.01), better cardiac output (116.2 ± 5.4 vs 88.8 ± 7.1 ml/min, p < 0.05), and higher coronary blood flow (25.0 ± 2.2 vs 14.9 ± 1.3 ml/min, p < 0.01). The coronary blood flow in response to acetylcholine was higher in the Telmisartan Group (47.8 ± 3.9 vs 28.0 ± 2.1 ml/min, p < 0.01), but there was no difference in response to sodium nitroprusside. The Telmisartan Group showed higher serum nitric oxide levels in the coronary effluent (33.9 ± 4.6 vs 20.6 ± 3.3 μmol/liter, p < 0.05). Conclusions: Treatment with the AT1 receptor antagonist improved ventricular and endothelial function after 24-hour heart preservation. These data imply that AT1 activation plays a critical role in reperfusion injury. AT1 receptor blockade may be a promising strategy for long-term heart preservation.",
author = "Noriyoshi Kajihara and Takahiro Nishida and Noriko Boku and Hideki Tatewaki and Masataka Eto and Shigeki Morita",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/j.healun.2005.05.006",
language = "English",
volume = "24",
pages = "2211--2217",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "12",

}

TY - JOUR

T1 - Angiotensin II type 1 receptor antagonist protects ventricular and coronary endothelial function after 24-hour heart preservation

AU - Kajihara, Noriyoshi

AU - Nishida, Takahiro

AU - Boku, Noriko

AU - Tatewaki, Hideki

AU - Eto, Masataka

AU - Morita, Shigeki

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Background: Angiotensin II type 1 (AT1) receptor antagonists may enhance the cyclic guanosine monophosphate-nitric oxide system and thereby attenuate ventricular and coronary endothelial dysfunction after heart preservation. Methods: We used an isolated rabbit heart preparation perfused with blood from a support rabbit. The rabbit heart was excised, stored for 24 hours, and then perfused with blood from a support rabbit that was treated with an AT1 receptor antagonist (telmisartan; 5 mg/kg) or solvent. We evaluated the cardiac output with the working preparation, and coronary blood flow and coronary endothelial function with the Langendorff preparation. In addition, we measured the serum nitric oxide level in the coronary effluent. Results: The Telmisartan Group showed higher plasma angiotensin II levels (928.6 ± 136.2 vs 271.6 ± 81.6 pg/ml, p < 0.01), better cardiac output (116.2 ± 5.4 vs 88.8 ± 7.1 ml/min, p < 0.05), and higher coronary blood flow (25.0 ± 2.2 vs 14.9 ± 1.3 ml/min, p < 0.01). The coronary blood flow in response to acetylcholine was higher in the Telmisartan Group (47.8 ± 3.9 vs 28.0 ± 2.1 ml/min, p < 0.01), but there was no difference in response to sodium nitroprusside. The Telmisartan Group showed higher serum nitric oxide levels in the coronary effluent (33.9 ± 4.6 vs 20.6 ± 3.3 μmol/liter, p < 0.05). Conclusions: Treatment with the AT1 receptor antagonist improved ventricular and endothelial function after 24-hour heart preservation. These data imply that AT1 activation plays a critical role in reperfusion injury. AT1 receptor blockade may be a promising strategy for long-term heart preservation.

AB - Background: Angiotensin II type 1 (AT1) receptor antagonists may enhance the cyclic guanosine monophosphate-nitric oxide system and thereby attenuate ventricular and coronary endothelial dysfunction after heart preservation. Methods: We used an isolated rabbit heart preparation perfused with blood from a support rabbit. The rabbit heart was excised, stored for 24 hours, and then perfused with blood from a support rabbit that was treated with an AT1 receptor antagonist (telmisartan; 5 mg/kg) or solvent. We evaluated the cardiac output with the working preparation, and coronary blood flow and coronary endothelial function with the Langendorff preparation. In addition, we measured the serum nitric oxide level in the coronary effluent. Results: The Telmisartan Group showed higher plasma angiotensin II levels (928.6 ± 136.2 vs 271.6 ± 81.6 pg/ml, p < 0.01), better cardiac output (116.2 ± 5.4 vs 88.8 ± 7.1 ml/min, p < 0.05), and higher coronary blood flow (25.0 ± 2.2 vs 14.9 ± 1.3 ml/min, p < 0.01). The coronary blood flow in response to acetylcholine was higher in the Telmisartan Group (47.8 ± 3.9 vs 28.0 ± 2.1 ml/min, p < 0.01), but there was no difference in response to sodium nitroprusside. The Telmisartan Group showed higher serum nitric oxide levels in the coronary effluent (33.9 ± 4.6 vs 20.6 ± 3.3 μmol/liter, p < 0.05). Conclusions: Treatment with the AT1 receptor antagonist improved ventricular and endothelial function after 24-hour heart preservation. These data imply that AT1 activation plays a critical role in reperfusion injury. AT1 receptor blockade may be a promising strategy for long-term heart preservation.

UR - http://www.scopus.com/inward/record.url?scp=29144438956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144438956&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2005.05.006

DO - 10.1016/j.healun.2005.05.006

M3 - Article

C2 - 16364873

AN - SCOPUS:29144438956

VL - 24

SP - 2211

EP - 2217

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 12

ER -